[1]徐 杨,杜惠芬,李克生,等.再生基因4（REG4）真核表达载体的构建及其蛋白在HEK 293T 细胞中的表达、纯化[J].现代检验医学杂志,2023,38(04):35-39.[doi:10.3969/j.issn.1671-7414.2023.04.006]
　XU Yang,DU Huifen,LI Kesheng,et al.Construction of Eukaryotic Expression Vector of Regenerating Gene 4(REG4) and Expression and Purification of Its Protein in HEK 293T Cells[J].Journal of Modern Laboratory Medicine,2023,38(04):35-39.[doi:10.3969/j.issn.1671-7414.2023.04.006]
点击复制

再生基因4（REG4）真核表达载体的构建及其蛋白在HEK 293T 细胞中的表达、纯化()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年04期
页码:
35-39
栏目:
论著
出版日期:
2023-07-15

文章信息/Info

Title:
Construction of Eukaryotic Expression Vector of Regenerating Gene 4(REG4) and Expression and Purification of Its Protein in HEK 293T Cells
文章编号:
1671-7414（2023）04-035-05
作者:
徐 杨1; 杜惠芬1; 李克生1; 柴丹丹1; 石晓玲1; 连晓雯1; 张学良2
（1. 甘肃省医学科学研究院医学生物技术研究中心，兰州 730050；2. 甘肃省肿瘤医院消化肿瘤内科，兰州 730050）
Author(s):
XU Yang1;  DU Huifen1;  LI Kesheng1;  CHAI Dandan1;  SHI Xiaoling1;  LIAN Xiaowen1;  ZHANG Xueliang2
（1. Medical Biotechnology Research Center, Gansu Academy of Medical Science, Lanzhou 730050 China； 2. Department of Digestive Oncology, Gansu Provincial Cancer Hospital, Lanzhou 730050, China）
关键词:
再生基因4; 再生胰岛衍生蛋白IV; 真核表达; 人胚肾细胞 293T; 瞬时转染; 蛋白纯化
分类号:
Q786
DOI:
10.3969/j.issn.1671-7414.2023.04.006
文献标志码:
A
摘要:
目的　构建再生基因4（regenerating gene 4，REG4） 的真核表达载体， 转染人胚肾细胞293T（humanembryonic kidney 293T cells，HEK 293T），获得重组人再生胰岛衍生蛋白IV (regenerating islet-derived protein IV, RegIV)。方法　根据 NCBI 数据库REG4 基因序列进行基因优化、合成，将其克隆至pCDNA3.4 载体并进行双酶切和测序鉴定，通过转染试剂聚乙烯亚胺（polyethylenimine, PEI）将pCDNA3.4-REG4 质粒瞬时转染至HEK 293T 细胞（实验组），同时以pEGFP-C1 质粒作为转染对照组，未转染重组质粒的HEK 293T 细胞作为空白对照组。荧光显微镜观察转染对照组转染效率，分别收集实验组及空白对照组细胞和细胞培养液上清，十二烷基硫酸钠聚丙烯酰胺凝胶电泳（sodiumdodecyl sulfate polyacrylamide gel electrophoresis，SDS-PAGE）与免疫印迹试验（Western-Blot，WB）检测Reg IV 蛋白表达水平。通过镍柱及丙烯葡聚糖凝胶 S-400 （Sephacryl S-400）柱进行蛋白纯化，SDS-PAGE 及WB 对纯化后重组蛋白进行鉴定。结果　经测序和双酶切鉴定，重组质粒pCDNA3.4-REG4 构建成功。转染对照组（pEGFP-C1 质粒）荧光显微镜观察结果显示转染效率约50%，表明转染成功。WB 结果显示仅在实验组（pCDNA3.4-REG4 质粒）的细胞中检测到Reg IV 蛋白。镍柱纯化时目的蛋白无法与镍柱填料有效结合，Sephacryl S-400 凝胶柱层析纯化获得了此重组蛋白。结论　成功构建了REG4 基因真核表达载体并在HEK 293T 细胞中成功表达，为深入研究Reg IV 蛋白的作用机理及开发潜在的抗癌靶向药物奠定了基础。
Abstract:
Objective　To construct an eukaryotic expression vector of Regenerating gene 4 (REG4) and transfection into human embryonic kidney 293T Cells (HEK 293T) to obtain recombinant human regenerating islet-derived protein IV (Reg IV). Methods　 The REG4 gene sequence was optimized and synthesized according to the NCBI database, and it was cloned into the pCDNA3.4 vector and identified. The pCDNA3.4-REG4 plasmid was transiently transfected into HEK 293T cells by transfection reagent polyethylenimine (PEI) as the experimental group. The pEGFP-C1 plasmid was used as transfection control group, and the HEK 293T cells not transfected with the recombinant plasmid were used as the blank control group. The transfection efficiency of the transfection control group was observed by fluorescence microscope. The cells and cell culture supernatant of the experimental group and the blank control group were collected respectively. The expression level of Reg IV protein was detected by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western-Blot (WB). The protein was purified by nickel column and Sephacryl S-400 column, and the purified recombinant protein was identified by SDS-PAGE and WB. Results　The recombinant plasmid pCDNA3.4-REG4 was successfully constructed by sequencing and double enzyme digestion. The transfection control group (pEGFP-C1 plasmid) showed that the transfection efficiency was about 50%, indicating that the transfection was successful. WB results showed that Reg IV protein was detected only in the cells of the experimental group (pCDNA3.4-REG4 plasmid). The target protein could not effectively bind to the nickel column filler during nickel column purification, and the recombinant protein was purified by Sephacryl S-400 gel column chromatography. Conclusion　The eukaryotic expression vector of REG4 gene was successfully constructed and expressed in HEK 293T cells, which laid a foundation for further study of the mechanism of Reg IV protein and the development of potential anticancer targeted drugs.

参考文献/References:

[1] TAKASAWA S. Regenerating gene (REG) product and its potential clinical usage [J]. Expert Opinion on Therapeutic Targets, 2016, 20(5): 541-550.
[2] ZHANG Junyan, ZHU Zhi, MIAO Zhifeng, et al. The Clinical significance and mechanisms of REG4 in human cancers [J]. Frontiers in Oncology, 2020, 10:559230.
[3] ZHENG Huachuan, XUE Hang, ZHANG Congyu. REG4 promotes the proliferation and anti-apoptosis of cancer [J]. Frontiers in Cell and Developmental Biology, 2022, 10: 1012193.
[4] CHEN Zijing, DOWNING S , TZANAKAKIS E S . Four decades after the discovery of regenerating isletderived (Reg) proteins: current understanding and challenges[J]. Frontiers in Cell and Developmental Biology, 2019, 7:235.
[5] VANDERLAAG K, WANG Wei, FAYADAT-DILMAN L, et al. Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer [J]. International Journal of Cancer, 2012, 130(6): 1251-1263.
[6] DAI Juanjuan, HE Yan, JIANG Mingjie, et al. REG4 regulates pancreatic regeneration following pancreatitis via modulating the Notch signaling[J]. Journal of Cellular Physiology, 2021, 236(11): 7565-7577.
[7] 王燕云, 初丽敏, 王婵, 等. 早期胃癌患者外周血CDH-17,RHBDD1 和miR-135 表达水平与临床病理特征的相关性研究[J]. 现代检验医学杂志, 2022,37(5): 18-22. WANG Yanyun, CHU Limin, WANG Chan, et al. Correlation between the expression levels of CDH-17, RHBDD1 and miR-135 in peripheral blood and clinicopathological features in patients with early gastric cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 18-22.
[8] ZHANG Na, CHAI Dandan, DU Huifen, et al. Expression of Reg IV and SOX9 and their correlation in human gastric cancer [J]. BMC Cancer, 2018, 18(1): 344.
[9] LINK A J, LABAER J. Trichloroacetic acid (TCA) precipitation of proteins [J]. Cold Spring Harbor Protocols, 2011(8): 993-994.
[10] HWANG J H, YOON J, CHO Y H, et al. A mutant KRASinduced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling [J]. International Journal of Cancer, 2020, 146(10): 2877-2890.
[11] HU Guoyong, SHEN Jiaqin, CHENG Li, et al. Purification of a bioactive recombinant human Reg IV expressed in Escherichia coli[J]. Protein Expression and Purification, 2010, 69(2): 186-190.
[12] LI A, CRIMMINS D L, LUO Q, et al. Expression of a novel regenerating gene product, Reg IV, by high density fermentation in Pichia pastoris: production, purification, and characterization [J]. Protein Expression and Purification, 2003, 31(2): 197-206.
[13] KESIDIS A, DEPPING P, LOD? A, et al. Expression of eukaryotic membrane proteins in eukaryotic and prokaryotic hosts [J]. Methods, 2020, 180: 3-18.
[14] 蒋励萍, 陈露颖, 蒯佳婕, 等. 人源GRK2 的真核表达、纯化及活性检测[J]. 安徽医科大学学报, 2023,58(2)：179-184． JIANG Liping, CHEN Luying, KUAI Jiajie, et al. Eukaryotic expression, purification and activity identification of human His-GRK2 recombinant protein[J]. Acta Universitatis Medicinalis Anhui, 2023, 58(2):179-184.

备注/Memo

备注/Memo:
基金项目： 兰州市科技发展指导性计划项目（2019-ZD-131）：高性能抗RegIV 单克隆抗体的制备及鉴定；甘肃省自然科学基金项目（21JR7RA866）：PG，MUC1，HIK1083 联合检测在胃早癌诊断中的临床研究。
作者简介：徐杨（1981-），女，硕士，助理研究员，主要研究方向：医学生物技术、肿瘤分子生物学，E-mail：sissi_x@126.com。
通讯作者：李克生（1963-），男，博士，研究员，主要研究方向：医学生物技术、肿瘤分子生物学，E-mail：likesheng63@hotmail.com。
更新日期/Last Update: 2023-07-15